XML 39 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments
9 Months Ended
Sep. 30, 2013
Commitments [Abstract]  
Commitments [Text Block]
11.    Commitments
 
We have an agreement with KTB Tumorforschungs GmbH, or “KTB,” for the license of patent rights held by KTB for the worldwide development and commercialization of aldoxorubicin. Under the agreement, we must make payments to KTB in the aggregate of $7.5 million upon meeting clinical and regulatory milestones up to and including the product’s second final marketing approval. We also agreed to pay:
 
·  
commercially reasonable royalties based on a percentage of net sales (as defined in the agreement);
 
·  
a percentage of non-royalty sub-licensing income (as defined in the agreement); and
 
·  
milestones of $1 million for each additional final marketing approval that we obtain.
 
In the event that we must pay a third party in order to exercise our rights to the intellectual property under the agreement, we will deduct a percentage of those payments from the royalties due KTB, up to an agreed upon cap.